AUGERE MEDICAL AS

Facts

Source: Firmafakta, with business data from public registers.

organisasjonsnummer:

921501684

navn:

AUGERE MEDICAL AS

organisasjonsform:

kode:

AS

beskrivelse:

Aksjeselskap

naeringskode1:

kode:

72.100

beskrivelse:

Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk

antallAnsatte:

not reported by source

hjemmeside:

not reported by source

epostadresse:

not reported by source

telefon:

not reported by source

forretningsadresse:

adresse:

Nedre Vaskegang 6

poststed:

OSLO

postnummer:

0186

kommune:

OSLO

stiftelsesdato:

2018-09-21

registreringsdatoenhetsregisteret:

2018-10-04

aktivitet:

Utvikling, salg og forskning knyttet til medisinske produkter og annet, som naturlig faller sammen med dette.

vedtektsfestetFormaal:

Utvikling, salg og forskning knyttet til medisinske produkter og annet, som naturlig faller sammen med dette.

View the address in Geonorge

Board and other roles

Source: Firmafakta. Also see the separate Brønnøysund lookup under related lookups.

Bostyrer

• Bostyrer:

Daglig leder

• Daglig leder: Jon Helge Hoem

Regnskapsfører

• Regnskapsfører: STATEMENT AS

Revisor

• Revisor: UNIC REVISJON AS

Styre

• Styremedlem: Robert Sagaas
• Styremedlem: Kjetil Hestdal
• Styremedlem: Marte Høivik
• Styrets leder: Even Guttormsen

Owners

Source: Firmafakta shareholder dataset.

1. AM EQUITY AS – 22.01 % (39750 shares, share class: Ordinære aksjer)
2. SIMULA INNOVATION AS – 13.8 % (24930 shares, share class: Ordinære aksjer)
3. FARVATN VENTURE AS – 13.15 % (23750 shares, share class: Ordinære aksjer)
4. MP PENSJON PK – 13.15 % (23750 shares, share class: Ordinære aksjer)
5. THOMAS DE LANGE – 3.25 % (5875 shares, share class: Ordinære aksjer)
6. BOTANISK INVEST AS – 2.77 % (5000 shares, share class: Ordinære aksjer)
7. HYPERCUBE HOLDING AS – 2.77 % (5000 shares, share class: Ordinære aksjer)
8. MOTION VECTOR AS – 2.77 % (5000 shares, share class: Ordinære aksjer)
9. CARSTEN GRIWODZ – 2.47 % (4465 shares, share class: Ordinære aksjer)
10. DAG JOHANSEN – 2.47 % (4465 shares, share class: Ordinære aksjer)
11. PÅL HALVORSEN – 2.47 % (4465 shares, share class: Ordinære aksjer)
12. BLUEFIELD AS – 2.07 % (3744 shares, share class: Ordinære aksjer)
13. K OG K AS – 2.03 % (3671 shares, share class: Ordinære aksjer)
14. FORZASYS AS – 1.83 % (3300 shares, share class: Ordinære aksjer)
15. LOTHE HARALD ARNE – 1.38 % (2500 shares, share class: Ordinære aksjer)
16. KARI EIAN KROGSTAD – 0.97 % (1759 shares, share class: Ordinære aksjer)
17. FJELLSTAD HOLDING AS – 0.97 % (1750 shares, share class: Ordinære aksjer)
18. TOR JAN DEREK BERSTAD – 0.72 % (1300 shares, share class: Ordinære aksjer)
19. AKSLA HOLDING AS – 0.69 % (1250 shares, share class: Ordinære aksjer)
20. AUGERE MEDICAL AS – 0.69 % (1250 shares, share class: Ordinære aksjer)
21. ANDREAS PETLUND – 0.69 % (1249 shares, share class: Ordinære aksjer)
22. MICHAEL ALEXANDER RIEGLER – 0.58 % (1050 shares, share class: Ordinære aksjer)
23. A/S MILLENIUM – 0.55 % (1000 shares, share class: Ordinære aksjer)
24. OLE-CHRISTIAN SCHMIDT HAGENES – 0.55 % (1000 shares, share class: Ordinære aksjer)
25. BYHOLD AS – 0.42 % (750 shares, share class: Ordinære aksjer)
26. HÅVARD NYGAARD ESPELAND – 0.4 % (723 shares, share class: Ordinære aksjer)
27. TOMAS KUPKA – 0.39 % (707 shares, share class: Ordinære aksjer)
28. KRISTIAN ANDRESEN – 0.35 % (625 shares, share class: Ordinære aksjer)
29. TORE SOLBERG – 0.35 % (625 shares, share class: Ordinære aksjer)
30. MEDIONA GROWTH PARTNER AB – 0.34 % (615 shares, share class: Ordinære aksjer)
31. NAVINE INVEST AS – 0.34 % (615 shares, share class: Ordinære aksjer)
32. RAGNAR LANGSETH – 0.34 % (613 shares, share class: Ordinære aksjer)
33. MATAMA AS – 0.28 % (500 shares, share class: Ordinære aksjer)
34. SKAVAK INVEST AS – 0.28 % (500 shares, share class: Ordinære aksjer)
35. JOHAN MATTIS JEPPSSON – 0.23 % (419 shares, share class: Ordinære aksjer)
36. PIA HELEN SMEDSRUD – 0.22 % (400 shares, share class: Ordinære aksjer)
37. HÅVARD JOHANSEN DAGENBORG – 0.2 % (357 shares, share class: Ordinære aksjer)
38. KIM VIDAR ÅNONSEN – 0.17 % (300 shares, share class: Ordinære aksjer)
39. ACORN CAPITAL III AS – 0.14 % (250 shares, share class: Ordinære aksjer)
40. MOMBO AS – 0.14 % (250 shares, share class: Ordinære aksjer)
41. ORANGE CAPITAL AS – 0.14 % (250 shares, share class: Ordinære aksjer)
42. PETTER LANGELAND WEDUM – 0.14 % (250 shares, share class: Ordinære aksjer)
43. LARS AABAKKEN – 0.11 % (200 shares, share class: Ordinære aksjer)
44. EETEN-MATTIS JEPPSSON – 0.08 % (150 shares, share class: Ordinære aksjer)
45. JOHN ÅSBJØRN ESPELAND – 0.07 % (125 shares, share class: Ordinære aksjer)
46. MARKUS MANGERSNES DRANGE – 0.05 % (87 shares, share class: Ordinære aksjer)
47. DANIEL MORK ENGEN – 0.02 % (40 shares, share class: Ordinære aksjer)

Fetch a longer owner list

Company holdings

• AUGERE MEDICAL AS – 0.69 %

Grants and support

Sources provided through Firmafakta: Innovation Norway, the EU, the Research Council of Norway and SkatteFUNN.

Innovasjon Norge (5)

5 results

1. fylkesnavn:

   Akershus

   kommunenavn:

   Bærum

   org_nr:

   921501684

   bedriftsnavn:

   AUGERE MEDICAL AS

   virkemiddelkategori:

   Risikolån og garantier

   underkategori:

   Landsdekkende risikolån

   innvilget_belop:

   1500000

   innvilget_dato:

   26.03.19

   beslutningsenhet:

   IN Oslo Viken

   naringshovedgruppe:

   N - Faglig, vitenskapelig og teknisk tjenesteyting

   naring:

   72.100 Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk

   type_finansiering:

   Lån

2. fylkesnavn:

   Akershus

   kommunenavn:

   Bærum

   org_nr:

   921501684

   bedriftsnavn:

   AUGERE MEDICAL AS

   virkemiddelkategori:

   Innovasjonstilskudd

   underkategori:

   Mentortjenesten

   innvilget_belop:

   31500

   innvilget_dato:

   14.06.19

   beslutningsenhet:

   IN Oslo Viken

   naringshovedgruppe:

   N - Faglig, vitenskapelig og teknisk tjenesteyting

   naring:

   72.100 Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk

   type_finansiering:

   Tilskudd

3. fylkesnavn:

   Oslo

   kommunenavn:

   Oslo

   org_nr:

   921501684

   bedriftsnavn:

   AUGERE MEDICAL AS

   virkemiddelkategori:

   Ekstraordinære tiltak

   underkategori:

   Koronatiltak

   innvilget_belop:

   2974000

   innvilget_dato:

   12.08.20

   beslutningsenhet:

   IN Oslo Viken

   naringshovedgruppe:

   N - Faglig, vitenskapelig og teknisk tjenesteyting

   naring:

   72.100 Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk

   type_finansiering:

   Tilskudd

4. fylkesnavn:

   Oslo

   kommunenavn:

   Oslo

   org_nr:

   921501684

   bedriftsnavn:

   AUGERE MEDICAL AS

   virkemiddelkategori:

   Risikolån og garantier

   underkategori:

   Landsdekkende risikolån

   innvilget_belop:

   900000

   innvilget_dato:

   12.08.20

   beslutningsenhet:

   IN Oslo Viken

   naringshovedgruppe:

   N - Faglig, vitenskapelig og teknisk tjenesteyting

   naring:

   72.100 Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk

   type_finansiering:

   Lån

5. fylkesnavn:

   Akershus

   kommunenavn:

   Bærum

   org_nr:

   921501684

   bedriftsnavn:

   AUGERE MEDICAL AS

   virkemiddelkategori:

   Oppstartstilskudd

   underkategori:

   Landsdekkende etablerertilskudd

   innvilget_belop:

   100000

   innvilget_dato:

   08.11.18

   beslutningsenhet:

   IN Kommersialisering og vekst

   naringshovedgruppe:

   N - Faglig, vitenskapelig og teknisk tjenesteyting

   naring:

   72.100 Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk

   type_finansiering:

   Tilskudd

EU-tildelinger (0)

No registered grants.

Forskningsrådet (7)

7 results

1. id:

   76956

   prosjektnummer:

   346375

   prosjekttittel:

   ColoCompare: colonoscopy guidance and AI assisted procedure comparison

   prosjektstart:

   2024

   prosjektslutt:

   2027

   prosjektansvarlig_navn:

   AUGERE MEDICAL AS

   organisasjonsnummer:

   921501684

   sokt_belop:

   Gasteroenterologi

   tildelt_belop:

   0.0

   virkemiddel:

   Programmer

   aktivitet:

   Brukerstyrte innovasjonsprogrammer

2. id:

   76840

   prosjektnummer:

   345901

   prosjekttittel:

   AI-enhanced colon cancer detection

   prosjektstart:

   2023

   prosjektslutt:

   2023

   prosjektansvarlig_navn:

   AUGERE MEDICAL AS

   organisasjonsnummer:

   921501684

   sokt_belop:

   Onkologi

   tildelt_belop:

   0.0

   virkemiddel:

   Nettverkstiltak

   aktivitet:

   Internasjonale nettverkstiltak

3. id:

   70105

   prosjektnummer:

   332326

   prosjekttittel:

   AI for Colonoscopy: Detection, Guidance and Digital Health

   prosjektstart:

   2022

   prosjektslutt:

   2024

   prosjektansvarlig_navn:

   AUGERE MEDICAL AS

   organisasjonsnummer:

   921501684

   sokt_belop:

   Simulering, visualisering, signalbehandling, bildeanalyse

   tildelt_belop:

   0.0

   virkemiddel:

   Felleskostnader

   aktivitet:

   Utlysningsaktiviteter

4. id:

   73448

   prosjektnummer:

   337121

   prosjekttittel:

   AI for Endoscopy: Detection, Guidance and Assisted Video Comparison

   prosjektstart:

   2022

   prosjektslutt:

   2025

   prosjektansvarlig_navn:

   AUGERE MEDICAL AS

   organisasjonsnummer:

   921501684

   sokt_belop:

   Simulering, visualisering, signalbehandling, bildeanalyse

   tildelt_belop:

   0.0

   virkemiddel:

   Felleskostnader

   aktivitet:

   Utlysningsaktiviteter

5. id:

   68897

   prosjektnummer:

   327927

   prosjekttittel:

   Improved AI for Colonoscopy with Clinical Evaluation

   prosjektstart:

   2021

   prosjektslutt:

   2024

   prosjektansvarlig_navn:

   AUGERE MEDICAL AS

   organisasjonsnummer:

   921501684

   sokt_belop:

   Simulering, visualisering, signalbehandling, bildeanalyse

   tildelt_belop:

   0.0

   virkemiddel:

   Felleskostnader

   aktivitet:

   Utlysningsaktiviteter

6. id:

   53609

   prosjektnummer:

   296520

   prosjekttittel:

   Gastro-Intestinal Real-time Detection

   prosjektstart:

   2019

   prosjektslutt:

   2020

   prosjektansvarlig_navn:

   AUGERE MEDICAL AS

   organisasjonsnummer:

   921501684

   sokt_belop:

   Databaser og multimediasystemer

   tildelt_belop:

   0.0

   virkemiddel:

   Nettverkstiltak

   aktivitet:

   Systemtiltak

7. id:

   54168

   prosjektnummer:

   298862

   prosjekttittel:

   Bridging the Disciplinary gap for Computer Aided Diagnosis in Colonoscopy: Detection, Evaluation and Diagnostics

   prosjektstart:

   2019

   prosjektslutt:

   2024

   prosjektansvarlig_navn:

   AUGERE MEDICAL AS

   organisasjonsnummer:

   921501684

   sokt_belop:

   Systemutvikling- og arbeid

   tildelt_belop:

   3.83

   virkemiddel:

   Frittstående prosjekter

   aktivitet:

   Andre frittstående prosjekter

SkatteFUNN (5)

5 results

1. id:

   71734

   innsendt_dato:

   2024-08-30

   prosjektnummer:

   2208

   bedriftsnavn:

   AUGERE MEDICAL AS

   prosjekttittel:

   AI-drevet beslutningsstøtte for koloskopiundersøkelser

   organisasjonsnummer:

   921501684

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   not reported by source

   soknad_godkjent:

   not reported by source

   soknad_avslatt:

   not reported by source

   vedtaksdato:

   na

   prosjekt_fra_ar:

   2024

   prosjekt_til_ar:

   2026

   sammendrag:

   Reducing Human Variability in Medicine

2. id:

   68638

   innsendt_dato:

   2023-08-31

   prosjektnummer:

   348357

   bedriftsnavn:

   AUGERE MEDICAL AS

   prosjekttittel:

   Skattefunn: Next generation polyp detection to prevent Colorectal Cancer

   organisasjonsnummer:

   921501684

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2023-12-20

   prosjekt_fra_ar:

   2023

   prosjekt_til_ar:

   2023

   sammendrag:

   Gastrointestinal (GI) diseases are largely influencing quality of life with almost 3 million new GI cancers per year. The mortality is about 65%, but it is heavily influenced by early detection of neoplasia, where a 1% increase in detection can decrease the risk of cancer with 3%. For example, colon cancer is the third most common cause of cancer mortality, and it is a condition where early detection is important for survival, i.e., going from a low 10-30% 5-year survival probability if detected in later stages (III-IV) to a high 90% survival probability in early stages (I-II). Screening on a regular basis is therefore recommended, and the Norwegian Government has therefore decided to implement a national bowel screening program for 55 year old citizens starting from 2019 and providing full coverage by 2024. Colonoscopy will be a cornerstone in this program. A critical problem with colonoscopy, however, is the variability between the detection rate in performed procedures. Studies have shown that especially polyps of less than 10 mm, which with time may evolve into cancer, are overlooked very often, with a miss rate of 22%. The differences that occurs between endoscopists in and colorectal screening situation have shown to be significant. At the same time, studies have shown that in early detection of neoplasia, a 1% increase in detection can decrease the risk of cancer by 3%. This leaves a strong incentive for the development of tools that can aid the polyp detection rate. Image analysis powered by machine learning trained on datasets annotated by endoscopists can identify anomalies like bleeding and polyps in the video. Provided with high-quality training data, the finished model gives doctors real-time feedback based on the video feed from the procedure, identifying hard-to-detect polyps. Augere Medical is clinically evaluating such a tool that will soon to be available to the clinics.

3. id:

   66066

   innsendt_dato:

   2022-08-31

   prosjektnummer:

   340074

   bedriftsnavn:

   AUGERE MEDICAL AS

   prosjekttittel:

   Skattefunn: Real-time detection, data-retrieval and analysis for endoscopy

   organisasjonsnummer:

   921501684

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2022-12-16

   prosjekt_fra_ar:

   2022

   prosjekt_til_ar:

   2022

   sammendrag:

   Gastrointestinal (GI) diseases are largely influencing quality of life with almost 3 million new GI cancers per year. The mortality is about 65%, but it is heavily influenced by early detection of neoplasia, where a 1% increase in detection can decrease the risk of cancer with 3%. For example, colon cancer is the third most common cause of cancer mortality, and it is a condition where early detection is important for survival, i.e., going from a low 10-30% 5-year survival probability if detected in later stages (III-IV) to a high 90% survival probability in early stages (I-II). Screening on a regular basis is therefore recommended, and the Norwegian Government has therefore decided to implement a national bowel screening program for 55 year old citizens starting from 2019 and providing full coverage by 2024. Colonoscopy will be a cornerstone in this program. A critical problem with colonoscopy, however, is the variability between the detection rate in performed procedures. Studies have shown that especially polyps of less than 10 mm, which with time may evolve into cancer, are overlooked very often, with a miss rate of 22%. The differences that occurs between endoscopists in and colorectal screening situation have shown to be significant. At the same time, studies have shown that in early detection of neoplasia, a 1% increase in detection can decrease the risk of cancer by 3%. This leaves a strong incentive for the development of tools that can aid the polyp detection rate. Image analysis powered by machine learning trained on datasets annotated by endoscopists can identify anomalies like bleeding and polyps in the video. Provided with high-quality training data, the finished model gives doctors real-time feedback based on the video feed from the procedure, identifying hard-to-detect polyps. Augere Medical is clinically evaluating such a tool that will soon to be available to the clinics.

4. id:

   63480

   innsendt_dato:

   2021-09-01

   prosjektnummer:

   330899

   bedriftsnavn:

   AUGERE MEDICAL AS

   prosjekttittel:

   Skattefunn: Gastro-Intestinal Real-time Detection for Colonoscopy

   organisasjonsnummer:

   921501684

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2021-11-09

   prosjekt_fra_ar:

   2021

   prosjekt_til_ar:

   2021

   sammendrag:

   Gastrointestinal (GI) diseases are largely influencing quality of life with almost 3 million new GI cancers per year. The mortality is about 65%, but it is heavily influenced by early detection of neoplasia, where a 1% increase in detection can decrease the risk of cancer with 3%. For example, colon cancer is the third most common cause of cancer mortality, and it is a condition where early detection is important for survival, i.e., going from a low 10-30% 5-year survival probability if detected in later stages (III-IV) to a high 90% survival probability in early stages (I-II). Screening on a regular basis is therefore recommended, and the Norwegian Government has therefore decided to implement a national bowel screening program for 55 year old citizens starting from 2019 and providing full coverage by 2024. Colonoscopy will be a cornerstone in this program. A critical problem with colonoscopy, however, is the variability between the detection rate in performed procedures. Studies have shown that especially polyps of less than 10 mm, which with time may evolve into cancer, are overlooked very often, with a miss rate of 22%. The differences that occurs between endoscopists in and colorectal screening situation have shown to be significant. At the same time, studies have shown that in early detection of neoplasia, a 1% increase in detection can decrease the risk of cancer by 3%. This leaves a strong incentive for the development of tools that can aid the polyp detection rate. Image analysis powered by machine learning trained on datasets annotated by endoscopists can identify anomalies like bleeding and polyps in the video. Provided with high-quality training data, the finished model gives doctors real-time feedback based on the video feed from the procedure, identifying hard-to-detect polyps. Augere Medical is clinically evaluating such a tool that will soon to be available to the clinics.

5. id:

   55671

   innsendt_dato:

   2019-08-30

   prosjektnummer:

   307364

   bedriftsnavn:

   AUGERE MEDICAL AS

   prosjekttittel:

   Skattefunn: Gastro-Intestinal Real-time Detection for Colonoscopy

   organisasjonsnummer:

   921501684

   fylke:

   Oslo

   kommunenavn:

   Oslo

   poststed:

   OSLO

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2019-10-31

   prosjekt_fra_ar:

   2019

   prosjekt_til_ar:

   2020

   sammendrag:

   Gastrointestinal (GI) diseases are largely influencing quality of life with almost 3 million new GI cancers per year. The mortality is about 65%, but it is heavily influenced by early detection of neoplasia, where a 1% increase in detection can decrease the risk of cancer with 3%. For example, colon cancer is the third most common cause of cancer mortality, and it is a condition where early detection is important for survival, i.e., going from a low 10-30% 5-year survival probability if detected in later stages (III-IV) to a high 90% survival probability in early stages (I-II). Screening on a regular basis is therefore recommended, and the Norwegian Government has therefore decided to implement a national bowel screening program for 55 year old citizens starting from 2019 and providing full coverage by 2024. Colonoscopy will be a cornerstone in this program. A critical problem with colonoscopy, however, is the variability between the detection rate in performed procedures. Studies have shown that especially polyps of less than 10 mm, which with time may evolve into cancer, are overlooked very often, with a miss rate of 22%. The differences that occurs between endoscopists in and colorectal screening situation have shown to be significant. At the same time, studies have shown that in early detection of neoplasia, a 1% increase in detection can decrease the risk of cancer by 3%. This leaves a strong incentive for the development of tools that can aid the polyp detection rate. Image analysis powered by machine learning trained on datasets annotated by endoscopists can identify anomalies like bleeding and polyps in the video. Provided with high-quality training data, the finished model can give doctors real-time feedback based on the video feed from the procedure, identifying hard-to-detect polyps. Augere Medical is currently developing a such tool as a medical device to be connected to the endoscopy equipment, soon to be available to clinics.

Subunits

• AUGERE MEDICAL AS (921593058)

Open positions

count:

0

stillinger:

No results.

Related lookups

• Doffin notices where AUGERE MEDICAL AS is the buyer
• Search broadly for AUGERE MEDICAL AS in Doffin
• Open positions related to AUGERE MEDICAL AS
• Latest financial statement
• Patents and trademarks
• Official entity information from the Brønnøysund Register Centre
• Official roles from the Brønnøysund Register Centre
• Corporate group structure from the Brønnøysund Register Centre